Anti-CD25 Antibodies Deplete Tregs While Preserving IL-2 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD25 antibodies have not been clinically validated for treating cancer, and there is a need for effective antitumoral immunotherapies that modulate the IL-2/CD25 pathway to silence or eliminate regulatory T cells (Tregs) and restore antitumor immune functions.
Innovation Solution
Development of isolated anti-human CD25 antibodies or antigen-binding fragments with specific complementary-determining regions (CDRs) that mediate antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent phagocytosis, while avoiding inhibition of IL-2 signaling to deplete Tregs without affecting effector T cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD25 antibodies are used to deplete Tregs, then antitumor immune responses are enhanced, but IL-2 signaling to effector T cells may be inhibited
Solution Approach 1:
The antibody exhibits different functional properties at different locations: it binds to CD25 on Tregs to mediate depletion via ADC and CDC, while simultaneously allowing IL-2 binding to effector T cells through its unique CDR sequences that create spatially differentiated functional outcomes
Solution Approach 2:
The anti-CD25 antibody acts as an intermediary molecule that facilitates Treg depletion while preserving IL-2 signaling to effector cells, mediating between the need to eliminate suppressor cells and maintain stimulator cell function
2Reliability
If existing anti-CD25 antibodies are used, then Treg depletion is achieved, but clinical validation for cancer treatment is lacking
Solution Approach 1:
The invention modifies the CDR sequences of existing anti-CD25 antibodies to create novel variants with optimized binding affinity and functional properties, enabling clinical validation in cancer patients while maintaining Treg depletion capability
Solution Approach 2:
The patent uses humanized antibody sequences that copy and adapt successful preclinical mouse antibody designs (such as PC61) into human forms suitable for clinical trials, bridging the gap between preclinical efficacy and clinical application
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively deplete Tregs, enhancing antitumor immune responses by maintaining IL-2 signaling to effector T cells, thus offering a potent anti-cancer therapy by silencing Tregs without impairing immune stimulation.
Implementation Method 1
mediates antibody-dependent cellular cytotoxicity
Implementation Method 2
complement-dependent cytotoxicity
Implementation Method 3
antibody-dependent phagocytosis
Implementation Method 4
maintaining IL-2 signaling to effector T cells
Data Source
AI summary
Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.